PhotoPharmics

PhotoPharmics is a clinical-stage medical device company developing photo-neuromodulation therapies for neurodegenerative diseases, with an initial focus on Parkinson disease. The company investigational device, Celeste, is being studied to understand the role of retinal and circadian signaling pathways in Parkinson disease, addressing major unmet needs including sleep disturbances, fatigue, mood changes, cognitive difficulties, and disruptions to daily life. Celeste is a science-based, non-invasive, home-based device that delivers light through the eyes without surgery or implanted hardware. The company has published peer-reviewed Phase 2 clinical trial results in Neurotherapeutics and is conducting a Phase 3 pivotal trial nearing completion, with data readout anticipated at the World Parkinson Congress. PhotoPharmics participated in the AAN Annual Meeting and has expanded its board to support clinical execution, commercialization, and strategic partnerships. Parkinson disease affects more than 11 million people worldwide, with numbers expected to grow significantly. Founded in 2011 and headquartered in American Fork, United States, PhotoPharmics has raised approximately 45.7 million at the Series B stage with investors including Frazier VC, Kickstart Fund, HHS, ventureCapital.org, Frazier Group, UpStart Ventures, Kickstart Seed Fund, and MedTech Innovator.